Abstract:Aims: Perfluorocarbons (PFCs) are inert, oxygen-rich fluids with applications in neonatal and adult liquid ventilation and potential for innovations related to hypoxic environments, such as under water and for space. Despite promising clinical applications, a laboratory model to comprehensively test PFC implications and predict human airway responses is lacking. We hypothesise that an organotypic airway epithelial cell (AEC) model is needed assess PFC impacts and provide predictive outcomes to inform the in vivo scenario that conventional submerged cultures cannot replicate. This study evaluated PFC exposure in two in vitro systems: a traditional submerged model using 16HBE14o- cells and an air-liquid interface (ALI) model using hSABCi and primary nasal AECs, cultured on transwells to mimic the human airway epithelium. Methods: PFC exposures were conducted at 2, 8, and 24 hours (submerged model) and extended to 72 hours (ALI model). We tracked gross morphological changes via microscopy, quantified apoptosis and autophagy markers through protein biochemistry, and assessed epithelial permeability using trans-epithelial electrical resistance (TEER) and tight junction protein abundance. Statistical analyses included at least three biological replicates per condition. Results: In the submerged 16HBE14o- model, PFC exposure led to significant apoptotic changes by 24 hours, with marked autophagic disruption. Nutrient deprivation, confirmed by starvation experiments, was a key driver of cytotoxicity due to media/PFC phase separation. Conversely, hSABCi cells in the ALI model remained viable, with no apoptosis or autophagic disruption over the exposure periods (P > 0.05 vs. control). Similarly, primary nasal AECs showed consistent viability and stability in autophagic and apoptotic markers, indicating a more accurate representation of in vivo conditions. TEER measurements and tight junction protein levels in the ALI model suggested PFC did not compromise epithelial integrity (P > 0.05 vs. control). PBS exposure, included as a liquid control, underscored baseline sensitivity in the primary nAEC model, evidenced by SQSTM1 upregulation and pronounced barrier dysfunction over 24-72 hours (P < 0.05-0.001). These findings underscore the unique biocompatibility of PFC in maintaining cellular integrity, in contrast to the disruptive effects observed with PBS. Conclusion: This is the first study to describe PFC exposure in an organotypic airway model. Results indicate that the ALI model more accurately preserves airway epithelial integrity during PFC exposure than submerged models, which are limited by nutrient depletion effects. The findings support the use of ALI cultures to replicate the human airway architecture for evaluating PFC's biological effects and offer a platform for preclinical applications in respiratory medicine. This organotypic approach may inform future therapeutic and hypoxia-related interventions and contributes significantly to the field by providing a viable model for understanding PFC interactions with airway epithelial cells. We are now trialling PFC emulsions that also contain azithromycin and steroid therapies for extended therapeutic applications.

Inhaled fosamprenavir for laryngopharyngeal reflux: Toxicology and fluid dynamics modeling

Inhalation of Itraconazole Mitigates Bleomycin-Induced Lung Fibrosis Via Regulating SPP1 and C3 Signaling Pathway Pivotal in the Interaction Between Phagocytic Macrophages and Diseased Fibroblasts

Inhalable Advanced Co-Spray Dried Microparticles/Nanoparticles of a Novel RhoA/Rho Kinase Inhibitor with Lung Surfactant Biomimetic Phospholipids for Targeted Lung Delivery

Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose–response trial

Alveolar macrophage phagocytosis-evading inhaled microgels incorporating nintedanib-PLGA nanoparticles and pirfenidone-liposomes for improved treatment of pulmonary fibrosis

Advanced therapeutic inhalation aerosols of a Nrf2 activator and RhoA/Rho kinase (ROCK) inhibitor for targeted pulmonary drug delivery in pulmonary hypertension: design, characterization, aerosolization, in vitro 2D/3D human lung cell cultures, and in vivo efficacy

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients

Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis

A Phase I/IIa Prospective, Randomized, Open-Label Study on the Safety and Efficacy of Nebulized Liposomal Amphotericin for Invasive Pulmonary Aspergillosis

Designing Aerosol Therapies Based on the Integrated Evaluation of In Vitro, In Vivo, and In Silico Data

Efficacy and Safety of Admilparant, an LPA1 Antagonist in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial

Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials

Development of a novel, pan-variant aerosol intervention for COVID-19

Organotypic tissue architecture is a requisite for predictive outcomes of perfluorocarbon exposure in airway models

Inhaled nintentanib, pirfenidone and macitentan for pulmonary fibrosis: a laboratory experiment

Comparison of Oral, Intranasal and Aerosol Administration of Amiodarone in Rats as a Model of Pulmonary Phospholipidosis

Laminar Fluid Ejection for Olfactory Drug Delivery: A Proof of Concept Study

Oropharyngeal aspiration of bleomycin: An alternative experimental model of pulmonary fibrosis developed in Swiss mice

Efficacy of Liriope platyphylla extract on improving respiratory function: A CONSORT-randomized, double-blind, placebo-controlled pilot trial

An In Silico Investigation of a Lobe-Specific Targeted Pulmonary Drug Delivery Method

Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis